Objective. To evaluate the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response to or intolerance of tumor necrosis factor (TNF) inhibitors.
Objective. To evaluate the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response to or intolerance of tumor necrosis factor (TNF) inhibitors.
Methods. In this phase III study, 551 patients were randomized (1:1:1:1) to receive intravenous secukinumab at a dose of 10 mg/kg (at baseline and weeks 2 and 4) followed by subcutaneous secukinumab at a dose of either 150 mg or 75 mg every 4 weeks or, alternatively, abatacept or placebo on the same dosing schedule. The primary end point was the proportion of patients achieving 20% improvement in disease activity according to the American College of Rheumatology response criteria (ACR20) at week 24 in the secukinumab 150 mg or 75 mg treatment groups as compared with placebo. Key secondary end points included change from baseline to week 24 in the Disease Activity Score in 28 joints using C-reactive protein level (DAS28-CRP) and the Health Assessment Questionnaire disability index (HAQ DI), as well as the ACR 50% improvement (ACR50) response rate at week 24.
Results. The primary efficacy end point was met in patients receiving 150 mg secukinumab, in whom the ACR20 response rate at week 24 was significantly higher than that in the placebo group. The ACR20 response rates at week 24 were 30.7% in patients receiving 150 mg secukinumab (P 5 0.0305), 28 .3% in those receiving 75 mg secukinumab (P 5 0.0916), and 42.8% in those receiving abatacept, compared with 18.1% in the placebo group. A significant reduction in the DAS28-CRP was seen in patients treated with 150 mg secukinumab (P 5 0.0495), but not in patients treated with 75 mg secukinumab. Improvements in the HAQ DI and ACR50 response rates were not significant in the 2 secukinumab dose groups compared with the placebo group. The overall safety profile was similar across all treatment groups.
Conclusion. Secukinumab at a dose of 150 mg resulted in improvement in signs and symptoms and reduced disease activity in patients with active RA who had an inadequate response to TNF inhibitors. Improvements observed with abatacept were numerically higher than with secukinumab. There were no new or unexpected safety signals with secukinumab in this study.
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by progressive synovial inflammation and destruction of joint cartilage and bone (1) . RA affects ;0.5-1.0% of the population worldwide and is associated with decline in functional status, significant morbidity, reduced health-related quality of life, and premature mortality (2, 3) . Current guidelines recommend treatment with nonsteroidal antiinflammatory drugs (NSAIDs) or conventional synthetic diseasemodifying antirheumatic drug (csDMARD) therapy with or without concomitant glucocorticoid therapy as the first line of treatment (4) .
Tumor necrosis factor (TNF) inhibitors are considered the initial choice for patients in whom NSAIDs and csDMARDs are ineffective and/or for whom toxicity is a concern (4). However, alternatives to anti-TNF therapies are needed, since some patients treated with anti-TNF agents may have an inadequate treatment response or the medication may have unacceptable toxicity. Abatacept is one of the biologic DMARDs with proven efficacy in patients with RA who have an inadequate response to TNF inhibitors (5) . Abatacept selectively modulates a CD28-mediated costimulation required for full T cell activation (6) .
Interleukin-17A (IL-17A) has been considered a potential therapeutic target for the treatment of RA (7) (8) (9) (10) (11) (12) (13) . IL-17A, the principal effector cytokine of Th17 cells identified as being prominent in the pathogenesis of RA (14, 15) , has been implicated in the promotion of osteoclastogenesis (16) , cartilage breakdown (17) , and bone erosion (7) . Although IL-17A is elevated in the synovium of patients with RA (18), the exact role of IL-17 in comparison with other relevant inflammation pathways (19) in RA has not yet been studied in a large phase III trial.
Secukinumab is a high-affinity, fully human IgG1 monoclonal antibody that selectively binds to and neutralizes IL-17A. Secukinumab is approved for the treatment of moderate-to-severe psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS) (20) . Findings from a proof-of-concept trial and 3 phase II dose-finding trials have suggested that secukinumab may provide benefit for RA patients, although efficacy was variable between the different study populations (10, 21, 22) .
The present study evaluated the efficacy and safety of secukinumab compared with abatacept and placebo from a pivotal phase III active comparator-and placebocontrolled study in RA patients who had an inadequate response to or intolerance of TNF inhibitors. Data from a respective extension trial are also included in this report. However, due to early closure of the extension trial, only safety data are reported.
PATIENTS AND METHODS
Study design. This double-blind, double-dummy, randomized, parallel-group, active comparator-and placebocontrolled study was conducted across 121 centers in 15 countries. The study assessed efficacy at 24 weeks and up to 1 year in patients with active RA who had an inadequate response to TNF inhibitors. The study design is shown in Figure 1 . Patients who received secukinumab and who completed 1 year of treatment were eligible to join an extension study with a planned follow-up of a total of 5 years, although the mean total follow-up was 1.4 years due to early closure of the extension trial.
After a 4-week screening period, patients were randomly assigned (randomization ratio 1:1:1:1) to receive intravenous (IV) secukinumab at a dose of 10 mg/kg (at baseline and weeks 2 and 4) followed by subcutaneous (SC) secukinumab at a dose of either 150 mg or 75 mg every 4 weeks up to week 48 or, alternatively, abatacept (IV loading followed by monthly IV dosing: 500 mg for ,60 kg body weight, 750 mg for 60-100 kg body weight, and 1,000 mg for .100 kg body weight) or placebo on the same IV and SC dosing schedule (Figure 1 ).
At week 16, patients receiving placebo who were nonresponders (response defined as $20% improvement from baseline in both the tender joint count and swollen joint count) were rerandomized (1:1) to receive secukinumab at 150 mg SC or 75 mg SC every 4 weeks. Patients who were placebo responders at week 16 were rerandomized (1:1) to receive secukinumab at 75 mg SC or 150 mg SC every 4 weeks starting at week 24. Patients receiving abatacept who were nonresponders at week 16 were rerandomized (1:1) to receive secukinumab at 150 mg SC or 75 mg SC every 4 weeks starting at week 24, after an 8-week washout period during which they received placebo, administered in a blinded manner, at weeks 16 and 20.
A double-dummy design was used throughout the study, as the study treatments differed in their forms and routes of administration ( Figure 1 ). IV infusion bags with reconstituted secukinumab/placebo or abatacept/placebo solutions identical in appearance were used in the 52-week core study. At each treatment time point starting at week 8, 2 SC injections in the form of prefilled syringes (PFS) were administered, as secukinumab was available in either 0.5 ml (75 mg) PFS or 1.0 ml (150 mg) PFS. Placebo was also available in 0.5 ml and 1.0 ml PFS to match the active drug. Only patients who received secukinumab during the 52-week core study were eligible to participate in the extension study, during which they received the same dose of secukinumab as they had received in the core study.
Efficacy data are presented for the core study (placebocontrolled up to week 24). Safety information is presented from the entire core study and includes all available data from the extension study.
Patients. Patients at least 18 years of age who had been diagnosed at least 3 months before screening as having RA using the American College of Rheumatology/European League Against Rheumatism 2010 revised criteria for RA (23) were eligible for the study. Patients were also required to have active disease at baseline, defined as the presence of $6 tender joints (of 68 total) and $6 swollen joints (of 66 total), together with a positive result on either the anti-cyclic citrullinated peptide antibody test or the rheumatoid factor test, and either a high-sensitivity Creactive protein (hsCRP) level of $10 mg/liter or erythrocyte sedimentation rate (ESR) of $28 mm/first hour at screening. Patients had to have been receiving methotrexate (dosage of 7.5-25 mg/week) or any other DMARD for at least 3 months before randomization, and the DMARD should have been administered in a stable dose for at least 4 weeks before randomization. For any patients who were taking more than 1 DMARD, study participation was allowed after an appropriate washout period. Patients also had to have received at least 1 TNF inhibitor for at least 3 months before randomization and to have experienced an inadequate response to or intolerance of at least 1 dose of the anti-TNF agent. Patients may have been receiving more than 1 TNF inhibitor. The major exclusion criteria included ongoing rheumatic or inflammatory joint diseases other than RA, evidence of malignancy or infection seen on chest radiography, active tuberculosis infection, or previous use of biologic immunomodulating agents except for those targeting TNF.
The study protocol and all amendments were reviewed by the Independent Ethics Committee or Institutional Review Board for each center. The study was conducted in accordance with the ethics principles of the Declaration of Helsinki, and patients provided written informed consent before enrollment for the core study and separately for the extension study.
Outcome measures. The primary end point was the efficacy of secukinumab (administered at a dose of 150 mg or 75 mg) compared with placebo at week 24. Efficacy was measured as the proportion of patients achieving 20% improvement in disease activity based on the American College of Rheumatology response criteria (ACR20) (24) .
The key secondary efficacy outcome measures were the change from baseline in the Disease Activity Score in 28 joints (25) using C-reactive protein level (DAS28-CRP) and the Health Assessment Questionnaire disability index (HAQ DI) (26) as well as the proportion of patients achieving an ACR 50% improvement response (ACR50) at week 24. Other secondary efficacy end points included the ACR20, ACR50, and ACR70 (70% improvement) response rates and the change from baseline in the DAS28-CRP, the DAS28 using ESR (DAS28-ESR), and the HAQ DI at time points other than week 24. Subgroup analyses were conducted for a limited number of parameters, including baseline CRP level and change from baseline in the DAS28-CRP.
Safety was assessed throughout the core and extension periods by evaluation of all treatment-emergent adverse events (AEs) and serious AEs (SAEs), laboratory assessments, and assessment of immunogenicity (antisecukinumab antibodies). Safety analysis was performed separately for the initial period (up to week 16) and the entire treatment period including all available data from the extension study. Use of data up to and including week 16 provided an unbiased comparison between secukinumab, placebo, and abatacept, since, up to week 16, there was no switch in any treatment arm (see study design in Figure 1 ). Data collected beyond week 16 were included in analyses that summarized the entire treatment period, including the extension study.
Statistical analysis. Sample size calculations were performed using Fisher's exact test assuming an ACR20 response rate of 20% in the placebo group and 50% in the secukinumab dose groups at week 24. Including 137 patients per group with a Type I error rate of 2.5% provided 99% power to detect a difference between the secukinumab and placebo groups. The range of power for the secondary end points was between 89% and 99%.
The primary end point was analyzed via logistic regression analysis, with treatment as a factor and weight as a covariate. Odds ratios were computed for comparisons of the secukinumab regimens with the placebo regimen, utilizing a fitted logistic regression model. For patients meeting the criteria for early escape at week 16, their ACR20 response rate was set to nonresponse at week 24. This applied for all 4 treatment regimens in order to minimize bias. A hierarchical testing strategy was used to analyze the primary and secondary efficacy end points in order to maintain a family-wise error rate of 5% across the secukinumab groups and end points.
Binary variables up to week 24 were analyzed via a logistic regression model that included treatment as a factor and weight as 1146 BLANCO ET AL a covariate. Missing values, including those due to discontinuation of the study treatment, were imputed as nonresponses through week 24 (nonresponder imputation). Between-group differences in continuous variables up to week 24 were evaluated with the use of a mixed-effects model repeated-measures approach. Weight and baseline value of the outcome variable were included in the model as continuous covariates. Treatment by analysis visit and baseline score by analysis visit were included as interaction terms in the model. The analyses of efficacy variables were performed in all patients who were randomized and to whom study treatment had been assigned (full analysis set). The safety set comprised all patients who received at least 1 dose of the study drug during the treatment period. Up to week 16, safety group assignments were those determined by the randomization schedule (secukinumab, abatacept, or placebo); beyond week 16, safety is reported on the basis of the treatment assigned.
RESULTS
Characteristics of the patients. In total, 551 patients with RA were randomized to 1 of the 4 treatment groups, of whom 390 (70.8%) completed 52 weeks of treatment. Details of the disposition of patients and the reasons for discontinuation are shown in Figure 2 . The maximum exposure time for any secukinumab dose in the period including the extension study was 184 weeks, with a mean exposure of 537 days and a median exposure of 478 days.
The patients' demographic and baseline clinical characteristics were comparable across the treatment groups ( Table 1 ). The mean age ranged from 51.6 years to 55.9 years across the treatment groups. The majority of patients were female (77.5-86.2% across the treatment groups) and at least 70% in each group were white. Furthermore, 122 patients reported a previous exposure to more than 1 TNF inhibitor, and 52. Figure 2 . Disposition of patients. Patients were classified as responders or nonresponders at week 16 (W16) and were rerandomized to receive 75 mg secukinumab (sec) subcutaneously (SC) or 150 mg secukinumab SC. Only patients receving secukinumab at week 52 were eligible to enter the extension study. a 5 All of the patients in the abatacept group who completed treatment from week 1 to week 52 irrespective of rerandomization. b 5 All of the patients in the placebo group who completed treatment from week 1 to week 52. Groups in the boxes with broken outlines are rerandomized groups. receiving 75 mg secukinumab, and 42.8% among those receiving abatacept, compared with 18.1% in the placebo group (Table 2 and Figure 3A) . The primary end point of the ACR20 response rate at week 24 was met in patients receiving 150 mg secukinumab, whose ACR20 response rates were statistically significantly higher than those in the placebo group, as determined using the predefined statistical testing hierarchy (adjusted P 5 0.0305). For the secukinumab 75 mg group, the primary end point was not met (adjusted P 5 0.0916).
Key secondary efficacy results. The first key secondary end point, change in the DAS28-CRP from baseline to week 24, was met in the secukinumab 150 mg group, whose DAS28-CRP showed a statistically significant reduction at week 24, as determined using the predefined statistical testing hierarchy (adjusted P 5 0.0495) ( Figure 3B) . None of the other key secondary end points (HAQ DI and ACR50 response rates) were met in the secukinumab 150 mg group at week 24. In the secukinumab 75 mg group, none of the key secondary end points were met.
The least squares mean (LSM) change in the DAS28-CRP from baseline to week 24 was 21.47 in both secukinumab dose groups, 22.07 in the abatacept group, and 21.02 in the placebo group. The LSM change in the HAQ DI from baseline to week 24 was 20.39 in the secukinumab 150 mg group, 20.30 in the secukinumab 75 mg group, 20.61 in the abatacept group, and 20.26 in the placebo group. The ACR50 response rates at week 24 were 16.8% in those receiving 150 mg secukinumab, 11.6% in those receiving 75 mg secukinumab, 27.5% in those receiving abatacept, and 9.4% in those receiving placebo (Table 2) .
Other secondary efficacy results. The trends in the ACR50 and ACR70 response rates were similar to those in the ACR20 response rate up to week 24 ( Table 2) . Patients who received secukinumab showed numerically * TJC 5 tender joint count; SJC 5 swollen joint count; RA 5 rheumatoid arthritis; DAS28-CRP 5 Disease Activity Score in 28 joints using C-reactive protein level; DAS28-ESR 5 DAS28 using erythrocyte sedimentation rate; hsCRP 5 high-sensitivity C-reactive protein; anti-CCP 5 anti-cyclic citrullinated peptide; HAQ DI 5 Health Assessment Questionnaire disability index; MTX 5 methotrexate. † Negative was defined as a rheumatoid factor (RF) titer of ,14 units/ml. ‡ These patients who had not previously taken anti-tumor necrosis factor (anti-TNF) agents were protocol deviators. § These patients who previously took other biologic disease-modifying antirheumatic drugs (DMARDs) were protocol deviators.
higher response rates at week 24, both with the ACR50 (in both secukinumab dose groups) and the ACR70 (only in the secukinumab 150 mg group), as compared with patients who received placebo. The ACR50 and ACR70 responses were higher in the abatacept dose group compared with both secukinumab dose groups. ACR20, ACR50, and ACR70 responses achieved at week 24 were sustained up to week 52 in both secukinumab dose groups (Table 2) . Reductions in the mean DAS28-CRP from baseline up to week 24 were greater in patients receiving either of the secukinumab regimens compared with those receiving placebo. DAS28-CRP response rates were sustained from week 8 through week 52 in both secukinumab dose With regard to the DAS28-ESR, the LSM change from baseline was greater in both secukinumab dose groups compared with the placebo group at all time points up to week 24. Specifically, at week 24, the DAS28-ESR LSM changes from baseline were 21.73 in the secukinumab 150 mg group (P 5 0.0232), 21.68 in the secukinumab 75 mg group (P 5 0.0385), and 22.31 in the abatacept group (P , 0.0001), as compared with 21.23 in the placebo group. The improvement in the DAS28-ESR achieved at week 24 was sustained through week 52 ( Table 2) .
The improvements in the HAQ DI score achieved at week 24 were sustained up to week 52 in both secukinumab dose groups. In addition, further improvements in the HAQ DI were seen in the abatacept group during this period ( Table 2) .
Safety. Initial 16-week period. As shown in Table  3 , treatment-emergent AEs were reported to occur in a higher proportion of patients in the secukinumab and abatacept groups compared with the placebo group in the initial 16-week period. The most frequently reported treatmentemergent AEs, by system organ class, were infections and infestations ( Table 3 ). Within that class, the most commonly reported AEs were influenza, upper respiratory tract infection, and nasopharyngitis. Musculoskeletal and connective tissue disorders as well as gastrointestinal disorders occurred at comparable rates in patients in both secukinumab dose groups and the abatacept group (Table 3) .
During the initial 16-week period, the most commonly reported AEs, by preferred term, in the secukinumab group were diarrhea, headache, hypertension, and influenza (Table 3 ). The majority of AEs reported up to week 16 were mild or moderate in severity. During the initial 16-week period, 14 patients discontinued the study treatment due to an AE: 5 in each of the secukinumab groups, 3 in the abatacept group, and 1 in the placebo group (Table 3) .
The incidence of SAEs was low and comparable between the groups during the initial 16-week period ( Table 3 ). The incidence of AEs of special interest, which included major adverse cardiac events (MACEs), Candida infection, and neutropenia, was low during the initial 16-week period, including 3 cases of MACEs (all in the secukinumab 150 mg group), 7 cases of esophageal candidiasis, and 9 cases of neutropenia. One death was reported during the 16-week period, in the secukinumab 150 mg group. This was attributed to fulminant pulmonary artery embolism.
Entire treatment period. Treatment-emergent AEs were reported in a higher proportion of patients in the secukinumab and abatacept groups compared with the placebo group over the entire treatment period ( Table 3 ). The most frequently reported treatment-emergent AEs, by system organ class, were infections and infestations ( Table 3 ). Within that class, the most commonly reported AEs were nasopharyngitis and upper respiratory tract infection.
During the entire study period, rheumatoid arthritis, nasopharyngitis, upper respiratory tract infection, arthralgia, and hypertension were the most frequently reported AEs, by preferred term, in the secukinumab groups (Table 3) . Most of the AEs reported over the entire treatment period were mild or moderate in severity. During the entire study period, 43 patients discontinued the study treatment due to an AE (38 in the secukinumab groups and 5 in the abatacept group) ( Table 3) .
SAEs over the entire study period were reported at a rate of 9.7 per 100 patient-years (13.4%) in the secukinumab groups and 7.7 per 100 patient-years (6.6%) in the abatacept group (Table 3) . Among these SAEs, the most frequently affected system organ classes were musculoskeletal and connective tissue disorders, which occurred in 11 patients (5.1%) who received 150 mg secukinumab, 9 patients (4.1%) who received 75 mg secukinumab, and 1 patient (0.7%) who received abatacept.
In terms of AEs of special interest, the overall exposure-adjusted incidence rate (EAIR) of MACEs was 0.8 per 100 patient-years in the secukinumab groups and 0 per 100 patient-years in the abatacept group (Table 3) . For esophageal candidiasis and neutropenia, the EAIRs were low and similar between the active treatment groups (Table 3) . No cases of tuberculosis were reported.
Three deaths occurred during the entire treatment period after week 16. All of the deaths occurred in the secukinumab 75 mg group (1 of unknown cause and 2 due to cardiac insufficiency).
Treatment-emergent antisecukinumab antibodies (developing after secukinumab treatment in patients negative for these antibodies at baseline) were detected in 7 patients in the secukinumab groups. Antisecukinumab titers were measured and were low. Neutralizing antibodies were not detected.
DISCUSSION
Several phase II studies of secukinumab (12) and other IL-17A inhibitor molecules, such as ixekizumab, have demonstrated preliminary efficacy in the treatment of patients with RA (13, 27) . This is the first report to compare the efficacy of an IL-17A inhibitor with that of abatacept in a phase III randomized, double-blinded study of patients with RA in whom TNF inhibitor therapy has failed.
Secukinumab at a dose of 150 mg was statistically superior to placebo at week 24 in the treatment of patients with RA, and thus the primary end point of the study was achieved. A statistically significant change in the DAS28-CRP at week 24 was met only in the secukinumab 150 mg group, whereas none of the other key secondary end points, including the HAQ DI and the ACR50 response rate, were met. For the secukinumab 75 mg group, neither the primary end point nor any of the key secondary end points were met. Although this trial was not powered for intergroup statistical comparisons, it is noteworthy that the response to abatacept, as measured using the ACR20, ACR50, and ACR70 response rates, the DAS28-CRP, and the HAQ DI, indicated numerically larger responses in the abatacept group compared with the 2 secukinumab dose groups at most time points from week 8 through week 24 and up to week 52. Efficacy responses for abatacept were similar to those observed in other trials of this compound in patients in whom TNF inhibitor therapy has failed. The ACR50 response rate in patients receiving abatacept in this study (27.5% at week 24) was similar to the efficacy previously observed in phase III trials of abatacept in patients with an inadequate response to TNF inhibitors (20.3% at week 24) (5).
Other second-line therapies, including anti-IL-6 therapies such as tocilizumab (28) and B cell-targeting therapies such as rituximab (29) , have demonstrated good efficacy in RA patients in whom treatment with TNF inhibitors has failed. Indirect comparisons of efficacy from such agents, in conjunction with the results of the direct comparison against abatacept in this trial, suggest that inhibition of IL-17A with secukinumab proffers no additional benefit to RA patients with an inadequate response to TNF inhibitors over currently approved therapies. Thus, the extension period of this trial was closed early.
Safety data from this trial confirmed the safety profile of secukinumab as previously reported in phase III trials in patients with psoriasis, PsA, or AS, and these data allow for a comparison with abatacept in terms of common events such as infectious, gastrointestinal, and musculoskeletal AEs. With respect to rare events such as MACEs and deaths, no such events occurred in the abatacept and placebo groups, and therefore direct comparisons of EAIRs for these events were not possible in this trial. However, the EAIRs for MACEs and deaths are comparable to those observed for other biologic agents in patients with RA (30, 31) .
In conclusion, in this study, secukinumab at a dose of 150 mg demonstrated efficacy for the treatment of patients with active RA who had an inadequate response to TNF inhibitors. However, no incremental benefit of IL-17A inhibition was seen over other agents currently approved for use in patients in whom TNF inhibitors have failed. These data, along with the findings from phase II studies (11, 12) and data related to the use of other anti-IL-17A agents (13, 27) , suggest that IL-17A plays a lesser role in the pathogenesis of RA. Thus, blockade of IL-17A alone may not add to the armamentarium for clinicians in the treatment of patients with RA in whom anti-TNF therapy has failed. This stands in contrast to the results seen in patients with spondyloarthropathies, including PsA and AS, in whom inhibition of IL-17A with secukinumab has demonstrated robust efficacy. The safety profile of secukinumab in this study of patients with RA was comparable to the safety profile of secukinumab in PsA and AS.
